Sarcopenia Worsens Liver Transplant Outcomes for Patients With Cirrhosis
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 5, 2023 -- Sarcopenia is associated with adverse outcomes after liver transplantation (LT) in patients with decompensated cirrhosis (DC), according to a study published online Sept. 21 in the Journal of Cachexia, Sarcopenia, and Muscle.
Da Zhou, from Nanjing University in China, and colleagues investigated the association between sarcopenia and one-year overall survival (OS) in patients with DC after LT. The analysis included 177 consecutive patients undergoing LT (September 2020 to June 2022).
The researchers found that 41.2 percent of participants had sarcopenia, which was associated with a longer duration of intensive care unit stay (4.1 versus 3.1 days), a higher rate of major complications (45.2 versus 22.1 percent), and higher postoperative mortality (15.1 versus 2.9 percent). Median one-year OS after surgery was shorter in patients with sarcopenia versus without. Independent risk factors associated with one-year OS included sarcopenia (hazard ratio [HR], 2.54), weight loss ≥5 percent (HR, 2.46), and model for end-stage liver disease (MELD) score (HR, 1.05). The established dynamic nomogram had an area under the curve of 0.774, with the calibration curve showing good consistency and analysis of the decision curve showing more clinical benefits than the MELD score alone. The survival rate was significantly lower in high-risk patients (>102.9 points calculated using the nomogram).
"Sarcopenia is associated with adverse outcomes after LT in patients with DC," the authors write. "High-risk patients should be classified by dynamic nomogram upon admission."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 -- For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter...
Prevalence of Hepatitis Delta High in Hepatitis B Surface Antigen Chronic Carriers
THURSDAY, April 4, 2024 -- The prevalence of hepatitis delta virus (HDV) is high in hepatitis B surface antigen (HBs Ag) chronic carriers detected through annual screenings...
Heart Transplant Offer Acceptance Highest for White Women
TUESDAY, March 26, 2024 -- The cumulative incidence of heart transplant offer acceptance is highest for White women, according to a study published online March 25 in the Journal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.